Recommendations. This matter has been reviewed and approved by the Medical School Conflict of Interest Board. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University’s entering into this Agreement with ONL Therapeutics, Inc.
Appears in 4 contracts
Sources: Subcontract Agreement, Research Agreement, Research Agreement
Recommendations. This matter has been reviewed and approved by the Medical School Conflict of Interest Board. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University’s entering into amending this Agreement with ONL Oncopia Therapeutics, Inc.LLC.
Appears in 3 contracts
Sources: Research Agreement, Research Agreement, Research Agreement
Recommendations. This matter has been reviewed and approved by the Medical School Conflict of Interest Board. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University’s entering into this Agreement with ONL Verge Therapeutics, Inc.
Appears in 2 contracts
Sources: Sponsored Activity Agreement, Subcontract Agreement
Recommendations. This matter has been reviewed and approved by the Medical School Conflict of Interest Board. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University’s entering into this Agreement with ONL Decibel Therapeutics, Inc.
Appears in 2 contracts
Sources: Research Agreement, Research Agreement
Recommendations. This matter has been reviewed and approved by the Medical School Conflict of Interest Board. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University’s entering into this Agreement with ONL TherapeuticsPrehab Technologies, Inc.LLC dba Prenovo.
Appears in 1 contract
Sources: Subcontract Agreement
Recommendations. This matter has been reviewed and approved by the Medical School Conflict of Interest Board. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University’s entering into this Agreement with ONL ▇▇▇▇▇▇ Therapeutics, Inc.
Appears in 1 contract
Sources: Research Agreement
Recommendations. This matter has been reviewed and approved by the Medical School Conflict of Interest Board. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University’s entering into this Agreement with ONL between the University and OncoFusion Therapeutics, Inc.
Appears in 1 contract
Sources: License Agreement
Recommendations. This matter has been reviewed and approved by the Medical School Conflict of Interest Board. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University’s entering into this Agreement with ONL between the University and Diapin Therapeutics, Inc.LLC.
Appears in 1 contract
Sources: License Agreement
Recommendations. This matter has been reviewed and approved by the Medical School Conflict of Interest Board. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University’s entering into this Agreement with ONL Therapeuticsbetween the University and Morphomic Analysis Group, Inc.LLC.
Appears in 1 contract
Sources: Option Agreement
Recommendations. This matter has been reviewed and approved by the Medical School Conflict of Interest Board. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University’s entering into this Agreement with ONL Oncopia Therapeutics, Inc.LLC.
Appears in 1 contract
Sources: Research Agreement
Recommendations. This matter has been reviewed and approved by the Medical School Conflict of Interest Board. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University’s entering into amending this Agreement with ONL Therapeutics, Inc.PP2A Therapeutics Oy.
Appears in 1 contract
Sources: Research Agreement
Recommendations. This matter has been reviewed and approved by the Medical School Conflict of Interest Board. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University’s entering into this Agreement with ONL Millendo Therapeutics, Inc.
Appears in 1 contract
Sources: Research Agreement
Recommendations. This matter has been reviewed and approved by the Medical School Conflict of Interest Board. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University’s entering into this Agreement with ONL IFM Therapeutics, Inc.
Appears in 1 contract
Sources: Research Agreement
Recommendations. This matter has been reviewed and approved by the Medical School Conflict of Interest Board. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University’s entering into this Agreement with ONL Therapeutics, Inc.between the University and Elicit Software LLC.
Appears in 1 contract
Sources: License Agreement
Recommendations. This matter has been reviewed and approved by the Medical School Conflict of Interest Board. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University’s entering into this Agreement with ONL between the University and Niche Therapeutics, Inc.LLC.
Appears in 1 contract
Sources: License Agreement
Recommendations. This matter has been reviewed and approved by the Medical School Conflict of Interest Board. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University’s entering into this Agreement with ONL Therapeutics, between the University and OntMed Inc.
Appears in 1 contract
Sources: License Agreement
Recommendations. This matter has been reviewed and approved by the Medical School Conflict of Interest Board. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University’s entering into this Agreement with ONL Therapeutics, Inc.between the University and Mekanistic Therapeutics LLC.
Appears in 1 contract
Sources: License Agreement
Recommendations. This matter has been reviewed and approved by the Medical School Conflict of Interest Board. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University’s entering into this Agreement with ONL Therapeuticsbetween the University and Applied Morphomics, Inc.
Appears in 1 contract
Sources: License Agreement
Recommendations. This matter has been reviewed and approved by the Medical School Conflict of Interest Board. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University’s entering into this Agreement with ONL Therapeutics, Inc.PP2A Therapeutics Oy.
Appears in 1 contract
Sources: Sponsored Activity Agreement